Product Description
Cefmetazole 56796-20-4
AI Product Description
*The following content is generated by AI and is for reference only.
Cefmetazole is a potent, broad-spectrum cephamycin antibiotic belonging to the beta-lactam class of antimicrobial agents. Chemically known as (6R,7S)-7-[(2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-3-[[[1-methyl-1H-tetrazol-5-yl]thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, it possesses a unique chemical structure featuring an alpha-methoxy group at the C-7 position and a methyltetrazole thiomethyl side chain. This specific configuration significantly enhances its stability against many beta-lactamases produced by both Gram-positive and Gram-negative bacteria, distinguishing it from earlier-generation cephalosporins. The molecular formula of Cefmetazole is C18H19N9O5S2, and its unique identity is registered under CAS number 58638-55-2.
Clinically, Cefmetazole is primarily utilized for the treatment of serious infections caused by susceptible organisms. It demonstrates excellent activity against a wide range of pathogens, including *Escherichia coli*, *Klebsiella* species, *Proteus mirabilis*, *Enterobacter* species, *Haemophilus influenzae*, and various anaerobic bacteria such as *Bacteroides fragilis*. Due to its robust coverage of anaerobes and resistance to enzymatic degradation, it is frequently prescribed for intra-abdominal infections, pelvic inflammatory disease, gynecological infections, skin and soft tissue infections, and respiratory tract infections. Furthermore, it serves as an effective prophylactic agent in surgical settings, particularly in colorectal and gynecologic surgeries, to prevent postoperative infectious complications.
The drug is typically administered via intravenous or intramuscular routes, allowing for rapid therapeutic blood levels. While generally well-tolerated, potential adverse effects may include gastrointestinal disturbances, rash, transient elevation of liver enzymes, and rare cases of hypersensitivity reactions. As with all beta-lactam antibiotics, caution is advised for patients with a history of severe penicillin allergy due to the risk of cross-reactivity. Its ability to penetrate tissues effectively, combined with its favorable pharmacokinetic profile, makes Cefmetazole a valuable asset in modern antimicrobial therapy, especially in scenarios requiring coverage against resistant strains or mixed aerobic-anaerobic infections. Continuous monitoring of susceptibility patterns remains essential to ensure optimal clinical outcomes and combat emerging resistance mechanisms.